You have read all your free articles, to continue reading subscribe to read the rest of this content.
Brilinta reduced the risk of the composite of stroke and death after an acute ischaemic stroke or transient ischaemic attack. Results from the Phase III THALES trial showed AstraZeneca’s Brilinta (ticagrelor) 90mg used twice daily and taken with aspirin for 30 days, reached a statistically signAlready a subscriber Login You…
The company announces the status of the ongoing phase I/IIa clinical trial CANFOUR investigating the lead compound CAN04 (nidanilimab) and further information on the phase IIa part of the trial. So far, 15 patients have received therapy in the phase I safety part of the study, and generally the iAlready…
Lytix Biopharma has announced data from its ATLAS-IT-04 trial in patients with metastatic soft tissue sarcoma (STS). The data from this Phase II proof of concept study shows that LTX-315 in combination with Adoptive Cell Therapy (ACT) was able to stabilize the disease in 3 out of 4 fully treated…
All safety reviews during the dose escalation phase have been completed with no Dose Limiting Toxicities (DLT) reported and the five US hospital sites are now open for further recruitment. This phase I/II trial investigates the safety, biologic and anti-tumor activity of ONCOS-102 in combination Already a subscriber Login You…
